ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Other Equity
ScinoPharm Taiwan Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Other Equity
-NT$28.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Other Equity
-NT$270.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-28%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Other Equity
-NT$15.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Other Equity
-NT$1.4B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Other Equity
NT$4.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Other Equity?
Other Equity
-28.6m
TWD
Based on the financial report for Dec 31, 2024, ScinoPharm Taiwan Ltd's Other Equity amounts to -28.6m TWD.
What is ScinoPharm Taiwan Ltd's Other Equity growth rate?
Other Equity CAGR 5Y
22%
Over the last year, the Other Equity growth was 68%. The average annual Other Equity growth rates for ScinoPharm Taiwan Ltd have been 29% over the past three years , 22% over the past five years .
You don't have any saved screeners yet